OPINIONSmall-Cap Stocks Are Doing Something They Haven't Done Consistently in 3 YearsBy Brian SozziMar 14, 2018 6:23 PM EDT
STOCKSXBiotech cancer drug survival claim falls apart under scrutinyBy Adam FeuersteinJul 5, 2016 8:35 AM EDT
INVESTING4 Biotech Stocks Under $10 to Watch for Breakout TradesBy Roberto PedoneJul 2, 2014 8:18 AM EDT
OPINIONThe 5 Dumbest Things on Wall Street This Week: Aug. 23By Gregg GreenbergAug 23, 2013 7:00 AM EDT
STOCKSBiotech Stock Mailbag: Sarepta, Inovio, FDA Calendar, Ken Luskin's Angry Vical Voice MailBy Adam FeuersteinAug 9, 2013 6:00 AM EDT
STOCKSMannKind, Vical, GTx: Investors Predict Pivotal Clinical Trial ResultsBy Adam FeuersteinAug 4, 2013 5:00 PM EDT
STOCKSThe GTx Cancer Muscle-Wasting Drug Studies Will Fail. Here's WhyBy Adam FeuersteinJul 10, 2013 2:18 PM EDT
STOCKSGTx's CEO Discusses Q2 2012 Results - Earnings Call TranscriptBy Seeking AlphaAug 8, 2012 3:25 PM EDT
